Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: KAKALAK who wrote (2727)	10/21/1998 7:12:00 PM
From: westpacific	Read Replies (1) \| Respond to of 3725

Bruce: Read between the lines on this post of today, rather interesting. I feel that the management team is still pursuing an alliance with a drug company and this makes sense. Look at the recent McKesson and HBOC merger as an indication of this trend. The ability to utilize the deep pockets of a drug company to fund further research or even sales is strong. Think of the package potential of Imatron with a formulary packaged as a prevention Disease Management model to the managed care industry for Cardiac Risk. United Healthcare recently did a study with Cardiac Solutions that fits this trend. Just a thought and as always - long on Imatron with a large position. From the press release of 10/21/98 Each reported study used Imatron's EBCT to measure progression and regression of coronary artery calcium deposits. In some instances, the course of heart disease ranged from stabilization to regression, dependent upon the nature and duration of drug treatment or other intervention. These preliminary results were reported by Dr. Greg Brown in a double-blinded, placebo-controlled study at the University of Washington utilizing a combination of Simvastatin, Niacin and Antioxidants compared to a similar group receiving a placebo (non-treatment). The finding that treatment using a statin drug reduces progression of atherosclerosis was confirmed in an independent study from Harbor-UCLA medical center in Los Angeles. Commenting on the newly presented study findings, S. Lewis Meyer, President and CEO of Imatron said, ''It is critically important to note that not only is Imatron's coronary artery scan by EBT now being widely adopted to diagnose early stage coronary artery disease, but it is also being used to monitor the effectiveness of treatment in individual patients.